BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Peregrine Pharmaceuticals, Inc. 

14272 Franklin Avenue, Suite 100

Tustin  California  92780  U.S.A.
Phone: 714-508-6000 Fax: 714-838-5817


SEARCH JOBS

View Clinical Trials from BioPharm Insight





Collaborations

AVANIR Pharmaceuticals 





 Company News
Data Presented At American Association for Cancer Research Support Potential Of Peregrine Pharmaceuticals, Inc. (PPHM)'s PS-Targeting Immunotherapy Bavituximab To Enhance Anti-Tumor And Immune-Stimulating Effects Of Anti-CTLA-4 And Anti-PD-1 Treatments In Models Of Melanoma And Colon Cancer 4/9/2014 9:53:52 AM    More...
Data Presented At American Association for Cancer Research Support Potential Of Combining Peregrine Pharmaceuticals, Inc. (PPHM)'s PS-Targeting Immunotherapy Agent Bavituximab With Irradiation In Lung Cancer 4/8/2014 10:17:03 AM    More...
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Three Abstracts Accepted For Presentation At American Association for Cancer Research 2014 Annual Meeting 4/2/2014 11:06:28 AM    More...
Presentation At Annual Society Of Surgical Oncology Meeting Updates Progress In Investigator-Sponsored Phase 1/2 Trial Of Peregrine Pharmaceuticals, Inc. (PPHM)'s Bavituximab In Combination With Sorafenib In Liver Cancer 3/17/2014 11:01:36 AM    More...
Preclinical Data Presentations At Keystone Symposia Highlight Broad Immunotherapy Potential Of Peregrine Pharmaceuticals, Inc. (PPHM)' PS-Targeting Antibodies 3/14/2014 9:32:25 AM    More...
Peregrine Pharmaceuticals, Inc. (PPHM) Declares Quarterly Dividend On Its Series E Convertible Preferred Stock 3/12/2014 9:40:00 AM    More...
Data Presentations At Keystone Symposium Support Potential Of Peregrine Pharmaceuticals, Inc. (PPHM)' PS-Targeting Antibodies to Overcome Immune Suppression and Enhance Anti-Tumor Activity of Anti-CTLA-4 and PD-1 Antibodies 3/11/2014 10:30:23 AM    More...
Peregrine Pharmaceuticals, Inc. (PPHM) Reports Third Quarter Fiscal Year 2014 Financial Results And Recent Developments 3/10/2014 10:30:07 AM    More...
Peregrine Pharmaceuticals, Inc. (PPHM) PS-Targeting Immunotherapy Platform To Be Highlighted In Three Data Presentations At Keystone Symposia Conferences 3/5/2014 11:41:55 AM    More...
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Partial Exercise Of Overallotment Option In Connection With Preferred Stock Offering 2/28/2014 10:18:24 AM    More...
12345678910...